Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Inclusion/ Exclusion Baseline
Description Intervention
Criteria/ Population Measures Outcomes
Akhondzadeh et Frequency of contact Diagnostic tool/method:
Repetitive
al. 2010
during study: every 2 DSM-IV-TR score ≥6,
behavior:
(continued) weeks for 10 weeks clinical judgment,
ABC-C
behavioral observation and
Stereotypic
Concomitant therapies, semistructured interview
Behavior, mean ±
n (%):
with parent
SD:
NR N at enrollment:
G1:
G1: 20
Diagnostic category, n
Week 10:
G2: 20
(%):
3.57 ± 1.61
Autism: 40 (100)
G2:
N at follow-up:
Week 10:
G1: 20
G2: 20
Other characteristics:
Weight/kg, mean ± SD
5.59 ± 0.82
G1 and G2
(range):
significantly
G1: 27.90 ± 6.07 (20-41)
different based on
< 30 kg: 17(85)
groups x time
> 30 kg: 3(15)
interaction (P ≤
G2: 26.75 ± 6.85 (15-39)
0.0001)
< 30 kg: 17(85)
Problem
> 30 kg: 3(15)
behavior:
ABC-C
History of previous
Hyperactivity/Non
medications, n (%):
compliance, mean
G1:
± SD:
Risperidone: 12 (6)
G1:
Haloperidol: 2 (1)
Week 10:
G2:
8.92 ± 4.05
Risperidone: 13 (65)
Haloperidol: 3 (15)
G2:
Week 10:
12.59 ± 1.86
G1 and G2
significantly
different based on
groups x time
interaction (P ≤
0.0001)
Akhondzadeh et
al. 2010
(continued)
C-2
ABC-C Irritability,
mean ± SD:
G1:
Week 10:
7.14 ± 3.23
G2:
Week 10: 11.65 ±
1.72
G1 and G2
significantly
different based on
groups-by-time
interaction
(P ≤ 0.0001)
Extrapyramidal
Symptoms
Rating Scale, n
(%):
G1: 7 (35)
G2: 8(40)